Trastuzumab Deruxtecan Induces Complete Pathological Response in Oligometastatic HER2-Mutant NSCLC: Case Report

Background: HER2 exon 20 insertions are rare oncogenic driver mutations in non-small cell lung cancer (NSCLC). Trastuzumab deruxtecan (T-DXd) has proven efficacy in pretreated metastatic HER2-mutant NSCLC. However, its use as first-line therapy in oligometastatic settings remains undocumented. Case...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Laurenz Nagl, MD, Lena Horvath, MD, PhD, Arno Amann, MD, Lorenz Schreiner, MD, Michael Günther, MD, Herbert Maier, MD, Johannes Kerschbaumer, MD, PhD, Gerlig Widmann, MD, Danijela Minasch, MD, Lisa-Maria Rossetti, MD, Katharina Kostenzer, MD, Dominik Wolf, MD, Florian Augustin, MD, Andreas Pircher, MD, PhD
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2026-07-01
Saila:	JTO Clinical and Research Reports
Gaiak:	Oligometastatic NSCLC HER2 mutation Trastuzumab deruxtecan complete pathological response Case report
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2666364326000743
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!